Venetoclax Tablet
NDC Package 76462-0576-9

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Venetoclax tablets is a medication used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). This formulation utilizes a tablet delivery system. Marketed by Abbvie Biotechnology Ltd, this product is identified by NDC 76462-0576.

Identification & Billing

NDC Package Code
76462-0576-9
Package Description
14077 TABLET in 1 BOX
Product Code
76462-0576
11-Digit Billing Format
76462057609

Clinical Specifications

Proprietary Name
Venetoclax
Non-Proprietary Name
Venetoclax
Substance Name
Venetoclax
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Active Ingredient(s)
VENETOCLAX 100 mg/1
Usage Information
This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Abbvie Biotechnology Ltd
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
03-07-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76462-0576-9 identifies a specific commercial package of 14077 tablet in 1 box of Venetoclax (UNFINISHED drug), drug for further processing labeled by Abbvie Biotechnology Ltd. This tablet is formulated for use and contains venetoclax as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Biotechnology Ltd on March 07, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

How is this Abbvie Biotechnology Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76462057609. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
76462-0576-9
11-Digit CMS (5-4-2)
76462-0576-09

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.